Skip to main content

Table 1 Demographic and clinical characteristics

From: Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study

Parameter Value
Sample size, N 1477
Age, years, mean (SD) 68.42 (6.81)
Body mass index, kg/cm 2 , mean (SD) 25.73 (4.34)
Years postmenopause, mean (SD) 20.94 (8.65)
Racial origin, white, n (%) 1417 (96%)
Prevalent vertebral fracture a , n (%) 1038 (70%)
Femoral neck BMD T-scores, mean (SD), [min, max] −2.39 (0.57), [−4.5, 0.03]
Country of origin, n (%)  
Australia 63 (4.3%)
Canada 116 (7.9%)
New Zealand 21 (1.4%)
United States 1277 (86%)
Smoking status a (yes vs. no, n) 180 vs. 1271
Alcohol consumption (yes vs. no, n) 306 vs. 1171
Number of prevalent vertebral fracture a  
Mean (SD) 1.32 (1.38)
>Zero vs. zero 1038 vs. 439
Number of osteoporotic nonvertebral fracture  
Mean (SD) 0.98 (1.24)
>Zero vs. zero 797 vs. 680
Baseline lumbar spine BMD, mean (SD), [min, max] −2.51 (1.20), [−6.0, 3.0]
Family history of osteoporosis (yes vs. no/unknown) 469 vs. 1008
History of hysterectomy (yes vs. no, n) 411 vs. 1066
Marital status a (married vs. other, n) 823 vs. 648
Years of education, mean (SD) 13.81 (3.03)
Number of preexisting conditions, mean (SD) 10.37 (5.92)
  1. Abbreviations: BMD = bone mineral density; min = minimum; max = maximum; n/N = number; SD = standard deviation; vs. = versus.
  2. aTwenty-six subjects had no record of smoking status; six subjects had no record of marital status; three subjects had no record regarding number of prevalent vertebral fracture.